Markus Queisser
@mqueisser.bsky.social
Reposted by Markus Queisser
For readers interested in therapeutic strategies based on inducing proximity between proteins, such as Halda's RIPTACs, here's a review on the field www.nature.com/articles/s41...
rdcu.be/eQzXF
and a news story on RIPTACs www.nature.com/articles/d41...
rdcu.be/eQzXF
and a news story on RIPTACs www.nature.com/articles/d41...
Induced proximity-based therapeutic modalities - Nature Reviews Drug Discovery
Induced proximity modalities encompass monovalent and bifunctional agents, such as molecular glues and proteolysis-targeting chimeras, that induce an interaction between biomolecules to functionally m...
www.nature.com
November 18, 2025 at 3:25 PM
For readers interested in therapeutic strategies based on inducing proximity between proteins, such as Halda's RIPTACs, here's a review on the field www.nature.com/articles/s41...
rdcu.be/eQzXF
and a news story on RIPTACs www.nature.com/articles/d41...
rdcu.be/eQzXF
and a news story on RIPTACs www.nature.com/articles/d41...
Reposted by Markus Queisser
Reality check-ing biotech — with Derek Lowe
YouTube video by Endpoints News
m.youtube.com
November 20, 2025 at 6:11 PM
Reposted by Markus Queisser
Exciting @biorxivpreprint.bsky.social by the groups of @pjcossar.bsky.social and @alessiociulli.bsky.social. They use a molecular glue between 14-3-3 and an intrinsically disordered domain of ERα to develop a molecular glue-based PROTAC recruiting VHL. doi.org/10.1101/2025...
#TPD #ChemSky #ChemBio
#TPD #ChemSky #ChemBio
Induced ubiquitination of the partially disordered Estrogen Receptor alpha protein via a 14-3-3-directed molecular glue-based PROTAC design
Proteins lacking defined ligandable pockets remain challenging drug targets. Here, we develop a molecular glue-based PROTAC (MGPROTACs) approach that chemically conjugates a molecular glue stabilizer ...
doi.org
November 19, 2025 at 9:04 AM
Exciting @biorxivpreprint.bsky.social by the groups of @pjcossar.bsky.social and @alessiociulli.bsky.social. They use a molecular glue between 14-3-3 and an intrinsically disordered domain of ERα to develop a molecular glue-based PROTAC recruiting VHL. doi.org/10.1101/2025...
#TPD #ChemSky #ChemBio
#TPD #ChemSky #ChemBio
Reposted by Markus Queisser
That’s Elon Musk, Fellow of the Royal Society, I’ll have you know. Because the Royal Society can only seem to come up with throat-clearing noises as a response to these sorts of statements instead of actually throwing him out.
Elon Musk: "It is time for the English to ally with the hard men, like Tommy Robinson, and fight for their survival or they shall surely all die" 29th October 2025. 2 million views in its first hour.
October 29, 2025 at 11:22 AM
That’s Elon Musk, Fellow of the Royal Society, I’ll have you know. Because the Royal Society can only seem to come up with throat-clearing noises as a response to these sorts of statements instead of actually throwing him out.
Reposted by Markus Queisser
Three (3) Sustaining Innovation #PostDoc opportunities in fragment-based design at Astex Pharmaceuticals (Cambridge UK) ref: SI/0825 | closing: 30-Sep-2025 #FBD #FBDD #SBDD #MedChem #ChemBiol #StructBiol #ChemPostDoc #PostDocJobs #chemsky 🧪
www.cloudonlinerecruitment.co.uk/Astex/Vacanc...
www.cloudonlinerecruitment.co.uk/Astex/Vacanc...
Astex Careers
Astex Careers
Astex Pharmaceuticals is a world leader in innovative drug discovery and development. The company has successfully applied its proprietary Fragment-Based Drug Discovery platform to generate multiple new drug candidates that are progressing in clinical development. Successful collaborations have led to three launched oncology drugs (Kisqali® partnered with Novartis, Balversa® partnered with Janssen and Truqap™ partnered with AstraZeneca). Astex continues to grow and focuses on Neurological Disorders and Oncology.
www.cloudonlinerecruitment.co.uk
September 5, 2025 at 7:54 AM
Three (3) Sustaining Innovation #PostDoc opportunities in fragment-based design at Astex Pharmaceuticals (Cambridge UK) ref: SI/0825 | closing: 30-Sep-2025 #FBD #FBDD #SBDD #MedChem #ChemBiol #StructBiol #ChemPostDoc #PostDocJobs #chemsky 🧪
www.cloudonlinerecruitment.co.uk/Astex/Vacanc...
www.cloudonlinerecruitment.co.uk/Astex/Vacanc...
Reposted by Markus Queisser
Excited to share a new preprint from the lab. We show that PTMs like phosphorylation & glycosylation dynamically reshape proteome-wide ligandability in cells, including proteins like KRAS. Great collaboration with the Huang Lab, @forlilab.bsky.social and BMS. www.biorxiv.org/content/10.1...
Post-Translational Modifications Remodel Proteome-Wide Ligandability
Post-translational modifications (PTMs) vastly expand the diversity of human proteome, dynamically reshaping protein activity, interactions, and localization in response to environmental, pharmacologi...
www.biorxiv.org
August 3, 2025 at 2:36 PM
Excited to share a new preprint from the lab. We show that PTMs like phosphorylation & glycosylation dynamically reshape proteome-wide ligandability in cells, including proteins like KRAS. Great collaboration with the Huang Lab, @forlilab.bsky.social and BMS. www.biorxiv.org/content/10.1...
Reposted by Markus Queisser
What happens to science under autocracy? The rise of the National Socialist Party in 1930s Germany provides an (admittedly extreme) example. Prior to the early 1930s, scientists at German institutions won a third of Nobels. 10 years later, that number was 5%, and has never recovered.
May 16, 2025 at 6:17 PM
What happens to science under autocracy? The rise of the National Socialist Party in 1930s Germany provides an (admittedly extreme) example. Prior to the early 1930s, scientists at German institutions won a third of Nobels. 10 years later, that number was 5%, and has never recovered.
Reposted by Markus Queisser
An important safety manuscript for all working with CRBN binders or recruiters! Congratulations Lise Loberg at AbbVie and Katie Stamp at BMS for leading this cross-industry collaboration effort and all other contributors!
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
Nonclinical teratogenicity safety assessment of CRBN-engaging targeted protein degraders: Points to consider
Targeted protein degraders (or degraders) are an emerging small molecule drug modality with transformative therapeutic potential. Currently, most degr…
www.sciencedirect.com
March 3, 2025 at 7:27 PM
An important safety manuscript for all working with CRBN binders or recruiters! Congratulations Lise Loberg at AbbVie and Katie Stamp at BMS for leading this cross-industry collaboration effort and all other contributors!
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
Reposted by Markus Queisser
Small molecular weight drug molecules are products of design. Multiple characteristics are designed into one chemical structure. Read about how the combination of experimental data with calculated properties streamlines the discovery of oral designer PROTACs:
pubs.rsc.org/en/content/a...
@rsc.org
pubs.rsc.org/en/content/a...
@rsc.org
February 22, 2025 at 10:03 AM
Small molecular weight drug molecules are products of design. Multiple characteristics are designed into one chemical structure. Read about how the combination of experimental data with calculated properties streamlines the discovery of oral designer PROTACs:
pubs.rsc.org/en/content/a...
@rsc.org
pubs.rsc.org/en/content/a...
@rsc.org
Reposted by Markus Queisser
This_one_goes_to_eleven dot gif
I wrote last week urging Pharma CEOs to speak up about the Trump administration. Unfortunately, some of them have.
Pharma CEOS Speaking Up, Damn It
www.science.org
February 19, 2025 at 9:22 PM
This_one_goes_to_eleven dot gif
Wonderful Molecular Glue Summit in Boston. Key Learning: there are Molecular Glue Degrader (MGD), Competitive Molecular Glues (CMG), Allosteric Molecualr Glues (AMG) and Intramolecular Glues (IMG) - you just have to look for them !
January 31, 2025 at 7:35 PM
Wonderful Molecular Glue Summit in Boston. Key Learning: there are Molecular Glue Degrader (MGD), Competitive Molecular Glues (CMG), Allosteric Molecualr Glues (AMG) and Intramolecular Glues (IMG) - you just have to look for them !
Reposted by Markus Queisser
If we were good at “validating” targets, the clinical trial failure rate likely wouldn’t be what it is. It’s an argument for large investment in basic disease biology and better model systems. No tech that churns out more compounds against the wrong target is gonna fix that. 15/
January 16, 2024 at 6:38 PM
If we were good at “validating” targets, the clinical trial failure rate likely wouldn’t be what it is. It’s an argument for large investment in basic disease biology and better model systems. No tech that churns out more compounds against the wrong target is gonna fix that. 15/
Reposted by Markus Queisser
I liked that one!
A Rather Unwelcoming Degrader Enzyme
www.science.org
December 5, 2023 at 2:43 PM
I liked that one!